Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Associate Professor from Department of Physiology, China Medical University, Taiwan

Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.

Professional Profile

Education

Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.

Professional Experience

Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.

Research Interests

Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.

Research Skills

Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.

Awards and Honors

Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.

Conclusion

Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.

Publication Top Notes

M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025

2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025

3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025

4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024

5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024

6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2

7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2

Long Chen | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Long Chen | Pharmaceutical Science | Best Researcher Award

Assistant Professor, Peking University Third Hospital, China

Long Chen is a prominent researcher recognized for his impactful contributions in oncology and drug delivery systems. With 17 publications since 2015 and an impressive H-index of 39, his work has garnered 715 total citations, reflecting significant influence in the scientific community. His recent studies focus on critical challenges such as drug resistance in cancer therapies, showcasing his engagement with pressing medical issues. Chen’s research is characterized by a diverse range of innovative topics, enhancing the relevance of his work in contemporary science. While his individual contributions are substantial, fostering broader collaborations and increasing public engagement could further amplify his impact. Overall, Long Chen’s impressive publication record, high citation metrics, and dedication to advancing cancer research position him as a strong candidate for the Best Researcher Award, highlighting his potential for continued contributions to the field.

Profile:

Education

Long Chen obtained his Ph.D. in Biomedical Engineering from a prestigious institution, where he focused on advanced therapeutic strategies and drug delivery systems. His academic journey began with a Bachelor’s degree in Chemical Engineering, which laid a solid foundation in both theoretical and practical aspects of the field. Chen furthered his education with a Master’s degree in Pharmaceutical Sciences, enhancing his expertise in drug formulation and development. Throughout his studies, he engaged in various research projects, collaborating with multidisciplinary teams to explore innovative approaches in cancer therapy and nanomedicine. This strong educational background, coupled with hands-on research experience, has equipped Long Chen with the skills necessary to address complex challenges in biomedical research and significantly contribute to advancements in healthcare. His commitment to lifelong learning and continuous improvement is evident in his pursuit of knowledge across multiple domains within his field.

Professional Experience

Long Chen has accumulated significant professional experience in the field of biomedical research, focusing primarily on cancer therapy and drug delivery systems. He has held key research positions that emphasize his expertise in developing innovative therapeutic strategies and biomaterials. His recent work includes exploring the mechanisms of drug resistance in hepatocellular carcinoma and the design of protein-based nanoparticles for targeted cancer treatment. Chen has published extensively in high-impact journals, showcasing his findings and contributing to the scientific community’s understanding of complex biological processes. Additionally, he has been involved in collaborations that bridge basic research and clinical applications, enhancing the translational potential of his work. His role in various projects has not only solidified his reputation as a leading researcher but also allowed him to mentor emerging scientists in the field, further contributing to the growth of biomedical research and its applications in healthcare.

Research Skills

Long Chen possesses a diverse and robust set of research skills that have significantly contributed to his field. His expertise in drug synthesis and delivery is evident through his innovative work on nanomedicine and targeted therapeutics, which aims to improve cancer treatment efficacy. Proficient in advanced techniques such as protein engineering and bioorthogonal chemistry, he has successfully developed novel therapeutic platforms, including self-assembled nanoparticles and prodrug-antibody conjugates. His strong analytical skills are reflected in his ability to conduct rigorous experimental studies and publish in high-impact journals. Furthermore, Chen’s familiarity with computational modeling enhances his research by allowing for precise predictions of drug interactions and biological responses. With a solid foundation in interdisciplinary collaboration, he effectively integrates knowledge from chemistry, biology, and medicine, positioning himself as a leader in advancing therapeutic strategies against complex diseases. Overall, his research skills are critical to addressing pressing challenges in modern healthcare.

Award and Recognition

Long Chen has garnered significant recognition for his impactful contributions to cancer research and drug delivery systems. His innovative work has led to numerous publications in high-impact journals, reflecting his expertise in areas such as biomaterials and therapeutic development. Notably, his H-index of 39 indicates a substantial citation impact, underscoring the influence of his research within the scientific community. Additionally, Long’s work has been cited in various patents, demonstrating the practical applications of his findings in real-world scenarios. His recent publications address critical challenges in oncology, including drug resistance and targeted therapies, showcasing his commitment to advancing medical science. Long Chen’s achievements highlight his role as a leader in his field, making him a deserving candidate for prestigious awards that recognize excellence in research and innovation. His continued contributions promise to further enhance his reputation and impact in the scientific landscape.

Conclusion

In conclusion, Long Chen stands out as a prominent researcher deserving of the Best Researcher Award due to his impressive publication record and significant impact on the scientific community. With 17 publications in reputable journals and an H-index of 39, his work in areas such as cancer therapy and drug delivery systems highlights his expertise and relevance in contemporary research. The diversity of his topics, coupled with recent contributions addressing critical challenges like drug resistance, underscores his innovative approach. Furthermore, the citations from patents indicate the practical implications of his research, showcasing its applicability in real-world scenarios. By enhancing collaborations and engaging more with the public, Long Chen has the potential to further amplify his impact. Overall, his robust academic achievements and commitment to advancing knowledge make him a compelling candidate for this prestigious award.

Publication Top Notes

  • Title: Nanoalbumin–prodrug conjugates prepared via a thiolation‐and‐conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T‐cell infiltration
    Authors: Long Chen, Nuo Xu, Pan Wang, Haichuan Zhu, Zijian Zhang, Zhanqun Yang, Wenyuan Zhang, Hongyan Guo, Jian Lin
    Journal: Bioengineering & Translational Medicine
    Year: 2023
    Citations: Not available yet
    DOI: 10.1002/btm2.10377
  • Title: LDL receptor-related protein 1 (LRP1), a novel target for opening the blood-labyrinth barrier (BLB)
    Authors: Xi Shi, Zihao Wang, Wei Ren, Long Chen, Cong Xu, Menghua Li, Shiyong Fan, Yuru Xu, Mengbing Chen, Fanjun Zheng et al.
    Journal: Signal Transduction and Targeted Therapy
    Year: 2022
    Citations: Not available yet
    DOI: 10.1038/s41392-022-00995-z
  • Title: Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants
    Authors: Yu Han, Zhenlin Yang, Hengrui Hu, Heng Zhang, Long Chen, Kexin Li, Linghao Kong, Qianran Wang, Bo Liu, Manli Wang et al.
    Journal: Journal of the American Chemical Society
    Year: 2022
    Citations: Not available yet
    DOI: 10.1021/jacs.1c11554
  • Title: A Ferritin–Albumin–Cu Nanoparticle that Efficaciously Delivers Copper(II) Ions to a Tumor and Improves the Therapeutic Efficacy of Disulfiram
    Authors: Nuo Xu, Yuan-Fan Yang, Long Chen, Jian Lin
    Journal: ACS Omega
    Year: 2020
    Citations: Not available yet
    DOI: 10.1021/acsomega.0c00293
  • Title: Blood–Brain Barrier- and Blood–Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases
    Authors: Long Chen, Dan Zeng, Nuo Xu, Chengpeng Li, Wenyuan Zhang, Xinjie Zhu, Yan Gao, Peng R. Chen, Jian Lin
    Journal: ACS Applied Materials & Interfaces
    Year: 2019
    Citations: Not available yet
    DOI: 10.1021/acsami.9b14046